Pinpoint Therapeutics believes that the company’s approach to treat therapy-resistant cancers also may be effective against COVID-19.

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine, long-used malaria drugs to treat the illness caused by the novel coronavirus.

Two antimalarial strategies have been published from Imperial College London: new compounds that prevent the malaria parasite from infecting mosquitoes and gene-edited mosquitoes that cannot reproduce, leading to population destruction.